On May 6, 2020, Lineage Cell Therapeutics announced that it has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineageﾒs allogeneic dendritic cell therapy, toward development of a potential vaccine against SARS-CoV-2.